Is MGI a good stock to buy? Hits New 52-week High on Friday
MGI records money transfer revenue growth of 5% led by 10% YoY growth while MGO cross-border transaction sees 176% YoY
MGI records money transfer revenue growth of 5% led by 10% YoY growth while MGO cross-border transaction sees 176% YoY
BLRX trades on heavy volume after compelling Phase 3 Trials of Motixafortide (BL-8040) for the cancer treatment. BioLineRx Ltd. (BLRX), a clinical-stage
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.